Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
International Journal of Cardiology
|
September 28, 2016
Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives
Jennifer Cautela, Nathalie Lalevée, Chloé Ammar, et al.
Critical Reviews in Oncology/Hematology
|
October 6, 2009
2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group
Dominique Farge, Lise Bosquet, Diana Kassab-Chahmi, et al.
The Lancet. Gastroenterology & Hepatology
|
April 12, 2017
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial
Jean-Baptiste Bachet, Pascal Hammel, Jérôme Desramé, et al.
Cancer Medicine
|
July 18, 2019
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
Emilie Charton, Jean-Baptiste Bachet, Pascal Hammel, et al.
Annales Francaises D'Anesthesie Et De Reanimation
|
July 23, 2008
[Standards, Options: recommendations 2008; thromboembolic events treatment, prophylaxis and treatment of central venous catheter thrombosis in patients with cancer]
Irène Kriegel, Eric Desruennes, Marie-Cécile Douard, et al.
Bulletin Du Cancer
|
August 30, 2008
[2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients]
Philippe Debourdeau, Dominique Farge-Bancel, Lise Bosquet, et al.
Presse Medicale (Paris, France : 1983)
|
January 17, 2009
[Recommendations for venous thromboembolic events treatment and central venous catheter thrombosis management in cancer patients]
Antoine Elias, Philippe Debourdeau, Jean Marc Renaudin, et al.
Journal Des Maladies Vasculaires
|
November 15, 2008
[2008 Standards, Options: Recommendations for venous thromboembolic events(VTE)treatment and central venous catheter thrombosis(CVCT) management in cancer patients]
, Isabelle Mahé, Ismail Elalamy, et al.
The Lancet. Healthy Longevity
|
March 3, 2024
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial
Joël Guigay, Cécile Ortholan, Damien Vansteene, et al.
The Lancet. Healthy Longevity
|
May 17, 2024
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
Joël Guigay, Hervé Le Caer, François-Régis Ferrand, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
International Journal of Cardiology
|
September 28, 2016
Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives
Jennifer Cautela, Nathalie Lalevée, Chloé Ammar, et al.
Critical Reviews in Oncology/Hematology
|
October 6, 2009
2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group
Dominique Farge, Lise Bosquet, Diana Kassab-Chahmi, et al.
The Lancet. Gastroenterology & Hepatology
|
April 12, 2017
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial
Jean-Baptiste Bachet, Pascal Hammel, Jérôme Desramé, et al.
Cancer Medicine
|
July 18, 2019
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
Emilie Charton, Jean-Baptiste Bachet, Pascal Hammel, et al.
Annales Francaises D'Anesthesie Et De Reanimation
|
July 23, 2008
[Standards, Options: recommendations 2008; thromboembolic events treatment, prophylaxis and treatment of central venous catheter thrombosis in patients with cancer]
Irène Kriegel, Eric Desruennes, Marie-Cécile Douard, et al.
Bulletin Du Cancer
|
August 30, 2008
[2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients]
Philippe Debourdeau, Dominique Farge-Bancel, Lise Bosquet, et al.
Presse Medicale (Paris, France : 1983)
|
January 17, 2009
[Recommendations for venous thromboembolic events treatment and central venous catheter thrombosis management in cancer patients]
Antoine Elias, Philippe Debourdeau, Jean Marc Renaudin, et al.
Journal Des Maladies Vasculaires
|
November 15, 2008
[2008 Standards, Options: Recommendations for venous thromboembolic events(VTE)treatment and central venous catheter thrombosis(CVCT) management in cancer patients]
, Isabelle Mahé, Ismail Elalamy, et al.
The Lancet. Healthy Longevity
|
March 3, 2024
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial
Joël Guigay, Cécile Ortholan, Damien Vansteene, et al.
The Lancet. Healthy Longevity
|
May 17, 2024
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
Joël Guigay, Hervé Le Caer, François-Régis Ferrand, et al.
Page
of 7